Oncoceutics Acquisition - Consideration Paid and Purchase Price Allocation (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 07, 2021	Dec. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Asset Acquisition
IPR&D assets expensed			$ 0	$ 0	$ 82,890
Oncoceutics, Inc.
Asset Acquisition
Cash	$ 23,836
One-year closing anniversary payment	$ 14,000
Shares common stock issued as consideration (in shares)	8,723,769
Stock price per share on effective date (in dollars per share)	$ 4.98
Value of estimated common stock consideration	$ 43,445
Total consideration	81,281
Net assets acquired	(1,310)
IPR&D assets expensed	82,591
Total purchase price allocated	81,281
Transaction costs expensed to IPR&D	299
Transaction costs expensed to IPR&D	$ 82,890
Transaction expenses		$ 600